본문

서브메뉴

Combatting Bacterial Pathogens: Design, Evaluation, and Introduction of Novel Guanidinium-Rich Antibiotic Conjugates
Combatting Bacterial Pathogens: Design, Evaluation, and Introduction of Novel Guanidinium-...
Combatting Bacterial Pathogens: Design, Evaluation, and Introduction of Novel Guanidinium-Rich Antibiotic Conjugates

상세정보

자료유형  
 학위논문 서양
최종처리일시  
20260202104852
ISBN  
9798288817373
DDC  
610.28
저자명  
Chosy, Madeline.
서명/저자  
Combatting Bacterial Pathogens: Design, Evaluation, and Introduction of Novel Guanidinium-Rich Antibiotic Conjugates
발행사항  
[Sl] : Stanford University, 2023
발행사항  
Ann Arbor : ProQuest Dissertations & Theses, 2023
형태사항  
131 p
주기사항  
Source: Dissertations Abstracts International, Volume: 87-01, Section: B.
주기사항  
Advisor: Cegelski, Lynette.
학위논문주기  
Thesis (Ph.D.)--Stanford University, 2023.
초록/해제  
요약The global challenge of antibiotic resistance necessitates the introduction of more effective antibiotics. Antibiotic resistance can result in life-threating infections, where bacteria are able to survive even in the presence of high concentrations of antibiotics due to mechanisms such as drug efflux, target modification, and enzymatic deactivation of antimicrobials. Another challenge associated with difficult-to-treat bacterial infections is the formation of biofilms, or communities of bacterial cells enmeshed in a self-produced extracellular matrix. Biofilms can form on indwelling medical devices such as catheters and prosthetic joints and are often associated with chronic and recurrent infections. Many antibiotics target processes associated with active bacterial cell growth and division but are ineffective against the metabolically dormant or slow-growing cells found in bacterial biofilms. Antibiotics may also exhibit poor or incomplete penetration through the biofilm extracellular matrix. There is an urgent need for more antibiotics to treat urgent-threat pathogens, antibiotic-resistant strains, and bacterial biofilms. This dissertation describes the design, evaluation, and introduction of new antibiotic conjugates to combat bacterial pathogens. We report a potentially general design strategy, exemplified with vancomycin, that improves and expands antibiotic performance. Vancomycin is one of the most important antibiotics in use today for the treatment of Gram-positive infections. However, it fails to eradicate difficult-to-treat biofilm populations. Vancomycin is also ineffective in killing Gram-negative bacteria due to its inability to breach the outer membrane. Having shown previously that the spatial array (linear versus dendrimeric) of multiple guanidinium groups affects cell permeation, we report here for the first time vancomycin conjugates with dendrimerically displayed guanidinium groups that exhibit superior efficacy and breadth, with lead compound V-triguan-6C representing a broad-spectrum compound with excellent activity against VRE, Gram-negative ESKAPE pathogens, and S. aureus biofilms. Mode-of-action studies reveal cell-surface activity and enhanced vancomycin-like killing. The V-triguan conjugates exhibit no acute mammalian cell toxicity or hemolytic activity. We also investigated other cationic surrogates for the guanidinium group and evaluated the first vancomycin-biguanide antibiotic conjugates. One of these compounds-V-C6-Bg-ChloA-has the best broad-spectrum activity to-date, with efficacy against VRE, and Gram-negative pathogens as well as both Gram-positive and Gram-negative biofilms. Finally, we discuss the unique activity of vancomycin-octa-arginine (V-r8) against V. cholerae. V-r8 exhibits rapid killing against V. cholerae and results in the formation of intracellular inclusion bodies. Our studies introduce new classes of broad-spectrum vancomycin derivatives and highlight the potential to improve or expand antibiotic performance through combined mode-of-action and function-oriented design studies.
일반주제명  
Medical equipment
일반주제명  
Drug resistance
일반주제명  
Bacterial infections
일반주제명  
Staphylococcus infections
일반주제명  
Microbiology
일반주제명  
Pharmaceutical sciences
일반주제명  
Biochemistry
키워드  
Antibiotic resistance
키워드  
Enzymatic deactivation
키워드  
Biofilm extracellular matrix
기타저자  
Stanford University.
기본자료저록  
Dissertations Abstracts International. 87-01B.
전자적 위치 및 접속  
로그인 후 원문을 볼 수 있습니다.

MARC

 008260126s2023        us                              c    eng  d
■001000017359229
■00520260202104852
■006m          o    d                
■007cr#unu||||||||
■020    ▼a9798288817373
■035    ▼a(MiAaPQ)AAI32200979
■035    ▼a(MiAaPQ)Stanfordpn681dj3883
■040    ▼aMiAaPQ▼cMiAaPQ
■0820  ▼a610.28
■1001  ▼aChosy,  Madeline.
■24510▼aCombatting  Bacterial  Pathogens:  Design,  Evaluation,  and  Introduction  of  Novel  Guanidinium-Rich  Antibiotic  Conjugates
■260    ▼a[Sl]▼bStanford  University▼c2023
■260  1▼aAnn  Arbor▼bProQuest  Dissertations  &  Theses▼c2023
■300    ▼a131  p
■500    ▼aSource:  Dissertations  Abstracts  International,  Volume:  87-01,  Section:  B.
■500    ▼aAdvisor:  Cegelski,  Lynette.
■5021  ▼aThesis  (Ph.D.)--Stanford  University,  2023.
■520    ▼aThe  global  challenge  of  antibiotic  resistance  necessitates  the  introduction  of  more  effective  antibiotics.  Antibiotic  resistance  can  result  in  life-threating  infections,  where  bacteria  are  able  to  survive  even  in  the  presence  of  high  concentrations  of  antibiotics  due  to  mechanisms  such  as  drug  efflux,  target  modification,  and  enzymatic  deactivation  of  antimicrobials.  Another  challenge  associated  with  difficult-to-treat  bacterial  infections  is  the  formation  of  biofilms,  or  communities  of  bacterial  cells  enmeshed  in  a  self-produced  extracellular  matrix.  Biofilms  can  form  on  indwelling  medical  devices  such  as  catheters  and  prosthetic  joints  and  are  often  associated  with  chronic  and  recurrent  infections.  Many  antibiotics  target  processes  associated  with  active  bacterial  cell  growth  and  division  but  are  ineffective  against  the  metabolically  dormant  or  slow-growing  cells  found  in  bacterial  biofilms.  Antibiotics  may  also  exhibit  poor  or  incomplete  penetration  through  the  biofilm  extracellular  matrix.  There  is  an  urgent  need  for  more  antibiotics  to  treat  urgent-threat  pathogens,  antibiotic-resistant  strains,  and  bacterial  biofilms.  This  dissertation  describes  the  design,  evaluation,  and  introduction  of  new  antibiotic  conjugates  to  combat  bacterial  pathogens.  We  report  a  potentially  general  design  strategy,  exemplified  with  vancomycin,  that  improves  and  expands  antibiotic  performance.  Vancomycin  is  one  of  the  most  important  antibiotics  in  use  today  for  the  treatment  of  Gram-positive  infections.  However,  it  fails  to  eradicate  difficult-to-treat  biofilm  populations.  Vancomycin  is  also  ineffective  in  killing  Gram-negative  bacteria  due  to  its  inability  to  breach  the  outer  membrane.  Having  shown  previously  that  the  spatial  array  (linear  versus  dendrimeric)  of  multiple  guanidinium  groups  affects  cell  permeation,  we  report  here  for  the  first  time  vancomycin  conjugates  with  dendrimerically  displayed  guanidinium  groups  that  exhibit  superior  efficacy  and  breadth,  with  lead  compound  V-triguan-6C  representing  a  broad-spectrum  compound  with  excellent  activity  against  VRE,  Gram-negative  ESKAPE  pathogens,  and  S.  aureus  biofilms.  Mode-of-action  studies  reveal  cell-surface  activity  and  enhanced  vancomycin-like  killing.  The  V-triguan  conjugates  exhibit  no  acute  mammalian  cell  toxicity  or  hemolytic  activity.  We  also  investigated  other  cationic  surrogates  for  the  guanidinium  group  and  evaluated  the  first  vancomycin-biguanide  antibiotic  conjugates.  One  of  these  compounds-V-C6-Bg-ChloA-has  the  best  broad-spectrum  activity  to-date,  with  efficacy  against  VRE,  and  Gram-negative  pathogens  as  well  as  both  Gram-positive  and  Gram-negative  biofilms.  Finally,  we  discuss  the  unique  activity  of  vancomycin-octa-arginine  (V-r8)  against  V.  cholerae.  V-r8  exhibits  rapid  killing  against  V.  cholerae  and  results  in  the  formation  of  intracellular  inclusion  bodies.  Our  studies  introduce  new  classes  of  broad-spectrum  vancomycin  derivatives  and  highlight  the  potential  to  improve  or  expand  antibiotic  performance  through  combined  mode-of-action  and  function-oriented  design  studies.
■590    ▼aSchool  code:  0212.
■650  4▼aMedical  equipment
■650  4▼aDrug  resistance
■650  4▼aBacterial  infections
■650  4▼aStaphylococcus  infections
■650  4▼aMicrobiology
■650  4▼aPharmaceutical  sciences
■650  4▼aBiochemistry
■653    ▼aAntibiotic  resistance
■653    ▼aEnzymatic  deactivation  
■653    ▼aBiofilm  extracellular  matrix
■690    ▼a0487
■690    ▼a0410
■690    ▼a0572
■71020▼aStanford  University.
■7730  ▼tDissertations  Abstracts  International▼g87-01B.
■790    ▼a0212
■791    ▼aPh.D.
■792    ▼a2023
■793    ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17359229▼nKERIS▼z이  자료의  원문은  한국교육학술정보원에서  제공합니다.

미리보기

내보내기

chatGPT토론

Ai 추천 관련 도서


    신착도서 더보기
    최근 3년간 통계입니다.

    소장정보

    • 예약
    • 소재불명신고
    • 나의폴더
    • 우선정리요청
    • 비도서대출신청
    • 야간 도서대출신청
    소장자료
    등록번호 청구기호 소장처 대출가능여부 대출정보
    TF14900 전자도서 대출가능 마이폴더 부재도서신고 비도서대출신청 야간 도서대출신청

    * 대출중인 자료에 한하여 예약이 가능합니다. 예약을 원하시면 예약버튼을 클릭하십시오.

    해당 도서를 다른 이용자가 함께 대출한 도서

    관련 인기도서

    로그인 후 이용 가능합니다.